F Rudolf1, T L Haraldsdottir1, M S Mendes2, A-J Wagner2, V F Gomes2, P Aaby2, L Østergaard3, J Eugen-Olsen4, C Wejse5. 1. Bandim Health Project, International Network for the Demographic Evaluation of Populations and Their Health in Developing Countries Network, Bissau, Guinea-Bissau; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark. 2. Bandim Health Project, International Network for the Demographic Evaluation of Populations and Their Health in Developing Countries Network, Bissau, Guinea-Bissau. 3. Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark. 4. Bandim Health Project, International Network for the Demographic Evaluation of Populations and Their Health in Developing Countries Network, Bissau, Guinea-Bissau; Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark. 5. Bandim Health Project, International Network for the Demographic Evaluation of Populations and Their Health in Developing Countries Network, Bissau, Guinea-Bissau; GloHAU, Center for Global Health, School of Public Health, Aarhus University, Aarhus, Denmark.
Abstract
SETTING: The Bandim Health Project study area in Bissau, Guinea-Bissau. OBJECTIVE: To assess the potential usefulness of predictors (elsewhere applied) and clinical scores (TBscore and TBscore II) based on signs and symptoms typical of tuberculosis (TB) in case finding. DESIGN: Observational prospective cohort study of patients with signs and symptoms suggestive of pulmonary TB (PTB) from 2010 to 2012. RESULTS: We included 1089 PTB suspects with a mean age of 34 years (95%CI 33-35); human immunodeficiency virus (HIV) prevalence was 15.1%. PTB was diagnosed in 107 suspects (76.4% sputum smear-positive, 25.2% HIV-infected). Cough > 2 weeks had the highest diagnostic ability (area under the receiver operating characteristic curve [AUC] 0.66, 95%CI 0.62-0.71), while TBscore < 3 best excluded PTB (negative likelihood ratio [LR-] 0.3) when HIV status was not known. TBscore II ≥ 3 had the highest diagnostic ability in HIV-infected PTB suspects (AUC 0.62, 95%CI 0.53-0.72), while the absence of self-reported weight loss best excluded PTB (LR- 0.2). Cough > 2 weeks as a trigger for smear microscopy missed 32.1% of smear-positive PTB cases. CONCLUSION: Case finding could be improved by screening symptomatic adults for cough and/or weight loss using TBscore II as the trigger for smear microscopy. To suspect PTB only in patients with cough > 2 weeks (non-HIV-infected) or with current cough, fever, weight loss or night sweats (HIV-infected) was not effective in patients whose HIV status was unknown at first visit.
SETTING: The Bandim Health Project study area in Bissau, Guinea-Bissau. OBJECTIVE: To assess the potential usefulness of predictors (elsewhere applied) and clinical scores (TBscore and TBscore II) based on signs and symptoms typical of tuberculosis (TB) in case finding. DESIGN: Observational prospective cohort study of patients with signs and symptoms suggestive of pulmonary TB (PTB) from 2010 to 2012. RESULTS: We included 1089 PTB suspects with a mean age of 34 years (95%CI 33-35); human immunodeficiency virus (HIV) prevalence was 15.1%. PTB was diagnosed in 107 suspects (76.4% sputum smear-positive, 25.2% HIV-infected). Cough > 2 weeks had the highest diagnostic ability (area under the receiver operating characteristic curve [AUC] 0.66, 95%CI 0.62-0.71), while TBscore < 3 best excluded PTB (negative likelihood ratio [LR-] 0.3) when HIV status was not known. TBscore II ≥ 3 had the highest diagnostic ability in HIV-infected PTB suspects (AUC 0.62, 95%CI 0.53-0.72), while the absence of self-reported weight loss best excluded PTB (LR- 0.2). Cough > 2 weeks as a trigger for smear microscopy missed 32.1% of smear-positive PTB cases. CONCLUSION: Case finding could be improved by screening symptomatic adults for cough and/or weight loss using TBscore II as the trigger for smear microscopy. To suspect PTB only in patients with cough > 2 weeks (non-HIV-infected) or with current cough, fever, weight loss or night sweats (HIV-infected) was not effective in patients whose HIV status was unknown at first visit.
Authors: T T Balcha; S Skogmar; E Sturegård; T Schön; N Winqvist; A Reepalu; Z H Jemal; G Tibesso; J Björk; P Björkman Journal: Open Forum Infect Dis Date: 2014-10-10 Impact factor: 3.835
Authors: Kyle Fluegge; LaShaunda L Malone; Mary Nsereko; Brenda Okware; Christian Wejse; Hussein Kisingo; Ezekiel Mupere; W Henry Boom; Catherine M Stein Journal: BMC Public Health Date: 2018-06-26 Impact factor: 3.295
Authors: Yeqing Tong; Xuhua Guan; Shuangyi Hou; Li Cai; Yadong Huang; Lei Wang; Faxian Zhan; Yuqin Shi; Jiafa Liu Journal: Int J Environ Res Public Health Date: 2018-09-13 Impact factor: 3.390
Authors: Andrew F Auld; Andrew D Kerkhoff; Yasmeen Hanifa; Robin Wood; Salome Charalambous; Yuliang Liu; Tefera Agizew; Anikie Mathoma; Rosanna Boyd; Anand Date; Ray W Shiraishi; George Bicego; Unami Mathebula-Modongo; Heather Alexander; Christopher Serumola; Goabaone Rankgoane-Pono; Pontsho Pono; Alyssa Finlay; James C Shepherd; Tedd V Ellerbrock; Alison D Grant; Katherine Fielding Journal: PLoS Med Date: 2021-09-07 Impact factor: 11.069
Authors: Yasmeen Hanifa; Katherine L Fielding; Violet N Chihota; Lungiswa Adonis; Salome Charalambous; Nicola Foster; Alan Karstaedt; Kerrigan McCarthy; Mark P Nicol; Nontobeko T Ndlovu; Edina Sinanovic; Faieza Sahid; Wendy Stevens; Anna Vassall; Gavin J Churchyard; Alison D Grant Journal: PLoS One Date: 2017-08-03 Impact factor: 3.240
Authors: Tom H Boyles; Matilda Nduna; Thalitha Pitsi; Lesley Scott; Matthew P Fox; Gary Maartens Journal: Open Forum Infect Dis Date: 2020-01-06 Impact factor: 3.835
Authors: Yeonsoo Baik; Hannah M Rickman; Colleen F Hanrahan; Lesego Mmolawa; Peter J Kitonsa; Tsundzukana Sewelana; Annet Nalutaaya; Emily A Kendall; Limakatso Lebina; Neil Martinson; Achilles Katamba; David W Dowdy Journal: PLoS Med Date: 2020-11-10 Impact factor: 11.069